Hyperhomocysteinemia and homozygous MTHFR 677C>T mutation finding in an Alzheimer’s disease case with metabolic syndrome diagnosis

Dear Sir,
We read the manuscript entitled “Association between genetic and environmental factors and the risk of Alzheimer’s disease (AD)” written by Styczyn-ska M, Strosznajder JB, Religa D, et al. in your journal [4]. In this manuscript, the reported genetic factors (apolipoprotein E-Apo E, endothelial nitric oxide synthase-NOS3, methylenetetrahydrofolate reductase-“MTHFR”) were analyzed for the correlation with the environmental factors (homocysteine, vitamin B12, cholesterol) in the etiology of AD. The authors emphasize that the haplotype profiles of APOE epsilon 4 and NOS3 G alleles were not correlated with the homocysteine, vitamin B12, cholesterol status in the AD patients [4]. On the other hand we have an AD patient with homozygous type MTHFR 677C>T mutation with elevated homocystein level, vitamin B12 de-ficiency and hypercholesterolemia findings (Fig. 1). Additionally our patient had obesity, hypertension, diabetes mellitus type 2, deep vein thrombosis, thrombotic thrombocytopenia findings. Obesity, hypertension, hypercholesterolemia and diabetes mellitus were noticed in his family history. Due to these findings he had metabolic syndrome diagnosis [1]. In the patient’s physical examination, ulcerative lesions were observed on his legs probably due to diabetes mellitus and deep vein thrombosis (Fig. 2) [5]. He had also alcohol consumption history. MTHFR 677C>T, FV R506-Q506, FII prothrombin G20210A mutation analyses for the atherosclerosis findings, cytogenetic analyses in bone marrow samples for thrombotic thrombocytopenia findings were applied [6]. FV R506-Q506, FII prothrombin G20210A mutation analyses revealed no mutation and bone marrow cytogenetic analyses represented normal karyotype. Homozygous type MTHFR 677C>T mutation was observed which supports hyperhomocysteinemia findings. He had long term medication for his complains including B12 vitamin drugs.
As a life-style disorder, no role of the hyperhomocysteinemia with MTHFR 677C>T mutation in meta-bolic syndrome etiology was known. Hitherto, in our case homozygous type MTHFR 677C>T mutation with hyperhomocysteinemia may stimulate the metabolic syndrome findings. Also, atherosclerosis is a risk factor for vascular dementia and AD disease [2–4]. Methabolic syndrome and hyperhomocysteinemia with MTHFR 677C>T mutation findings cause the generalize atherosclerosis and these findings may be related to the AD in our case which emphasize Styczynska M, Strosznajder JB, Religa D, et al.’s manuscript findings [4].

References
1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
2. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer’s disease: a link to a vascular hypothesis? CNS Spectr 2008; 13: 606-613.
3. Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer’s disease. J Neurochem 2008; 106: 1503-1514.
4. Styczynska M, Strosznajder JB, Religa D, Chodakowska-Zebro­wska M, Pfeffer A, Gabryelewicz T, Czapski GA, Kobryś M, Karciauskas G, Barcikowska M. Association between genetic and environmental factors and the risk of Alzheimer’s disease. Folia Neuropathol 2008; 46: 249-254.
5. Sun J, Xu Y, Xue J, Zhu Y, Lu H. Methylenetetrahydrofolate reductase polymorphism associated with susceptibility to coronary heart disease in Chinese type 2 diabetic patients. Mol Cell Endocrinol 2005; 229: 95-101.
6. Van Amerongen G, Mathonnet F, Boucly C, Mathieu B, Vinatier I, Peltier JY, Catherine N, Collet C, de Mazancourt P. An improved method for the detection of the thermolabile variant of methylenetetrahydrofolate reductase. Clin Chem 1998; 44: 1045-1047.